Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Adial Pharmaceuticals Inc ADIL

Healthcare

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ADIL)

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 21, 2023

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float

GlobeNewswire August 4, 2023

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

GlobeNewswire July 11, 2023

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

GlobeNewswire June 1, 2023

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 12, 2023

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate's Assets and Business

GlobeNewswire May 10, 2023

Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update

GlobeNewswire March 30, 2023

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

GlobeNewswire March 21, 2023

Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

GlobeNewswire March 8, 2023

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

GlobeNewswire March 6, 2023

Adial Pharmaceuticals Schedules Business Update Conference Call

GlobeNewswire March 2, 2023

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

GlobeNewswire February 27, 2023

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

GlobeNewswire February 24, 2023

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

GlobeNewswire February 21, 2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

GlobeNewswire February 1, 2023

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 14, 2022

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic Pain

GlobeNewswire September 26, 2022

Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate's PNV-6005 as a Potential Treatment for Ulcerative Colitis

GlobeNewswire September 6, 2022

Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

GlobeNewswire August 22, 2022

Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 16, 2022